Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg

Osteoporosis International

Volumn 23, Issue 2, 2012, Pages 503-512

  Wark, J D ^a   Bensen, W ^b   Recknor, C ^c   Ryabitseva, O ^d   Chiodo III, J ^e   Mesenbrink, P ^f   De Villiers, T J ^g  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST JOSEPH S HOSPITAL   (Canada)

^c United Osteoporosis Centers   (United States)

^d Regional Hospital No 1   (Russian Federation)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Acetaminophen; Ibuprofen; Paracetamol; Zoledronic acid

Indexed keywords

IBUPROFEN; PARACETAMOL; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CHILL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; HYPOCALCEMIA; LIMB PAIN; MAJOR CLINICAL STUDY; MOUTH TEMPERATURE; MULTICENTER STUDY; MYALGIA; NAUSEA; NONCARDIAC CHEST PAIN; OSTEOPENIA; PAIN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY;

ACETAMINOPHEN; AGED; ARTHRALGIA; BODY TEMPERATURE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FEVER; HEADACHE; HUMANS; IBUPROFEN; IMIDAZOLES; MIDDLE AGED; NAUSEA; OSTEOPOROSIS, POSTMENOPAUSAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84857368765     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1563-8     Document Type: Article

References (7)

1. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 17476007 10.1056/NEJMoa067312 1:CAS:528:DC%2BD2sXltVSktLc%3D
2. KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 17878149 10.1056/NEJMoa074941 1:CAS:528:DC%2BD2sXht1Kit7nN
3. IR Reid GD Gamble P Mesenbrink P Lakatos DM Black 2010 Characterization of and risk factors for the acute-phase response after zoledronic acid J Clin Endocrinol Metab 95 4380 4387 20554708 10.1210/jc.2010-0597 1:CAS:528: DC%2BC3cXht1Wms73F
4. AJ Roelofs M Jauhiainen H Monkkonen MJ Rogers J Monkkonen K Thompson 2009 Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP Br J Haematol 144 245 250 19016713 10.1111/j.1365-2141.2008.07435.x
5. Hochberg Y (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802
6. W Strampel R Emkey R Civitelli 2007 Safety considerations with bisphosphonates for the treatment of osteoporosis Drug Saf 30 755 763 17722968 10.2165/00002018-200730090-00003 1:CAS:528:DC%2BD2sXht1amsb7F
7. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 16901023 10.4065/81.8.1013